BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12351951)

  • 1. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.
    Chung RT; Evans SR; Yang Y; Theodore D; Valdez H; Clark R; Shikuma C; Nevin T; Sherman KE;
    AIDS; 2002 Sep; 16(14):1915-23. PubMed ID: 12351951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3.
    Seminari E; Tinelli C; Ravasi G; Ripamonti D; Ladisa N; Marino N; Sighinolfi L; Mondello P; Migliorino M; Carosi G; Maserati R;
    Curr HIV Res; 2010 Apr; 8(3):186-93. PubMed ID: 20163342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C and progression of HIV disease.
    Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
    JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia.
    Taye S; Lakew M
    BMC Immunol; 2013 May; 14():23. PubMed ID: 23679118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
    Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.
    Ladep NG; Agaba PA; Agbaji O; Muazu A; Ugoagwu P; Imade G; Cooke G; McCormack S; Taylor-Robinson SD; Idoko J; Kanki P
    World J Gastroenterol; 2013 Mar; 19(10):1602-10. PubMed ID: 23538773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals.
    Kottilil S; Jagannatha S; Lu A; Liu S; McLaughlin M; Metcalf JA; Dewar R; Campbell C; Koratich C; Maldarelli F; Masur H; Polis MA
    HIV Clin Trials; 2004; 5(1):25-32. PubMed ID: 15002084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy.
    Yokozaki S; Takamatsu J; Nakano I; Katano Y; Toyoda H; Hayashi K; Hayakawa T; Fukuda Y
    Blood; 2000 Dec; 96(13):4293-9. PubMed ID: 11110704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of co-infection with hepatitis C virus and GB virus C on CD4 cell count and HIV-RNA level among HIV-infected patients treated with highly active antiretroviral therapy.
    Voirin N; Trépo C; Estève J; Chevallier P; Ritter J; Fabry J; Vanhems P
    AIDS; 2002 Jul; 16(11):1556-9. PubMed ID: 12131196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.
    De Luca A; Bugarini R; Lepri AC; Puoti M; Girardi E; Antinori A; Poggio A; Pagano G; Tositti G; Cadeo G; Macor A; Toti M; D'Arminio Monforte A;
    Arch Intern Med; 2002 Oct; 162(18):2125-32. PubMed ID: 12374521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients.
    Carmo RA; Guimarães MD; Moura AS; Neiva AM; Versiani JB; Lima LV; Freitas LP; Rocha MO
    Braz J Infect Dis; 2008 Jun; 12(3):173-9. PubMed ID: 18833399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can HCV affect the efficacy of anti-HIV treatment?
    Filippini P; Coppola N; Scolastico C; Liorre G; Nocera R; Sagnelli E; Piccinino F
    Arch Virol; 2000; 145(5):937-44. PubMed ID: 10881680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of IL-2 on hepatitis C virus RNA levels in patients co-infected with human immunodeficiency virus receiving HAART.
    Tedaldi EM; Chen L; Markowitz N; Kelly L; Abrams D;
    J Viral Hepat; 2005 Jul; 12(4):414-20. PubMed ID: 15985013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria.
    lsa SE; Gwamzhi LN; Akolo C; Giyan J
    Niger J Med; 2010; 19(3):279-85. PubMed ID: 20845631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.
    Yacisin K; Maida I; Ríos MJ; Soriano V; Núñez M
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):935-40. PubMed ID: 18593347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
    Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
    Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.